University of Navarra
Latest From University of Navarra
Iterum Therapeutics and Genoa Pharmaceuticals topped the list of biopharmaceutical start-up firms closing new venture capital rounds in May with $65m and $62m, respectively, to advance drug candidates for bacterial infections and idiopathic pulmonary fibrosis.
As academic labs fill gaps in discovery work once performed by biopharma companies, Roche is confident that a U.S. consortium of academic drug-discovery units will lead to broader partnerships between industry and academia and within the academy itself. Plus, MedImmune acquires ADC specialist Spirogen and other deals from the past week.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.